Understanding the clinical and biological aspects of monkeypox disease
Description of the Kinetics of the Clinical and Biological Aspects of the Persons Consulting in the Framework of the Management of the MONKEYPOX Disease
This study is trying to learn more about monkeypox by looking at the health and biological details of people who are getting vaccinated or diagnosed with the disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 330 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Pasteur Industry-sponsored |
| Locations | 1 site (Paris) |
| Trial ID | NCT05627713 on ClinicalTrials.gov |
What this trial studies
This study focuses on the clinical and biological characteristics of monkeypox disease, particularly in light of recent outbreaks in non-endemic countries. It is a descriptive, prospective, monocentric, longitudinal study where participants will be enrolled during consultations for vaccination or diagnosis of monkeypox. Data on socio-demographics, clinical status, and treatment will be collected, along with biological samples for various analyses including serological, virological, and genetic studies. The goal is to enhance understanding of the disease and improve management strategies.
Who should consider this trial
Good fit: Ideal candidates include adults eligible for monkeypox vaccination or suspected of having a monkeypox infection.
Not a fit: Patients who have already been vaccinated against monkeypox without proof or those with contraindications to vaccination may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved vaccination strategies and better management of monkeypox outbreaks.
How similar studies have performed: Other studies on monkeypox and similar viral infections have shown promise in understanding disease dynamics and improving public health responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult, * eligible for MPXV vaccination according to HAS criteria or suspected of MPXV infection * whose health status is compatible with a 45 ml single blood sample * who have consented to participate in the study * who are covered by a Social Health Insurance plan Exclusion Criteria: * Person with MPXV vaccination without proof of vaccination. * For persons presenting for MPXV vaccination: presence of a contraindication to vaccination other than a current infection. * Pregnant and lactating women * Person unable to give informed consent to participate
Where this trial is running
Paris
- Centre Médical de l'Institut Pasteur — Paris, France (Recruiting)
Study contacts
- Principal investigator: Fabien Taieb, MD — Institut Pasteur
- Study coordinator: Fabien Taieb, MD
- Email: fabien.taieb@pasteur.fr
- Phone: + 33(0)1 40 61 38 44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.